5 unknown. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Unknown 5 |
Follow Toripalimab: new trials by email Literature Review of Toripalimab trials Research Report on Toripalimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma EP/EC+PD-1 - Toripalimab, First-line Treatment | Phase 2 | Unknown | Sun Yat-sen University | 33 | 2023-02-18 | 2023-03-08 |
| HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama Hepatic arterial infusion chemotherapy, Bevacizumab, Toripalimab - Hepatocellular Carcinoma, Bevacizumab | Phase 2 | Unknown | Sun Yat-sen University | 30 | 2021-01-01 | 2020-11-13 |
| Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial Toripalimab - Nasopharyngeal Carcinoma, Toripalimab | Phase 2 | Unknown | Cancer Hospital of Guangxi Medical University | 40 | 2020-06-28 | 2021-08-20 |
| Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma Toripalimab combine with Rituximab - Diffuse Large B-cell Lymphoma, Rituximab | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 20 | 2020-06-15 | 2020-06-16 |
| Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC) Anlotinib Plus Toripalimab - Gastric Cancer, Immunotherapy | Phase 2 | Unknown | Shanghai Changzheng Hospital | 24 | 2020-02-10 | 2024-07-10 |
Carcinoma, Hepatocellular (1) · Liver Neoplasms (1) · Lymphoma, Large B-Cell, Diffuse (1) · Nasopharyngeal Carcinoma (1) · Stomach Neoplasms (1)
Neoplasms (4) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Carcinoma (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Liver Diseases (1)
toripalimab (3) · Bevacizumab (1) · Carboplatin (1) · Cisplatin (1) · Etoposide (1) · Rituximab (1) · anlotinib (1)
Sun Yat-sen University (2) · Cancer Hospital of Guangxi Medical University (1) · Chinese Academy of Medical Sciences (1) · Shanghai Changzheng Hospital (1)
China (4)
Fei Gao (1) · Kangshun Zhu, Professor (1) · Yanxia Shi (1)
PMID 11224527, PMID 16382236, PMID 18173375, PMID 30207593, PMID 35623069